Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis

Coronary Artery Disease

Volumn 25, Issue 8, 2014, Pages 638-644

  Nojima, Yuhei ^a   Yasuoka, Yoshinori ^a   Kume, Kiyoshi ^a   Adachi, Hidenori ^a   Hattori, Susumu ^a   Matsutera, Ryo ^a   Kohama, Yasuaki ^a   Sasaki, Tatsuya ^a  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

Drug eluting stent; Heterogeneous drug eluting stent; Homogeneous drug eluting stent; In stent restenosis; Switching types (drug coating or generation) of drug eluting stent

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOLIMUS ELUTING STENT; CONTROLLED STUDY; CORONARY STENTING; DIABETES MELLITUS; DRUG ELUTING CORONARY STENT; EVEROLIMUS ELUTING STENT; FEMALE; HEART INFARCTION; HEMODIALYSIS; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SIROLIMUS ELUTING STENT; ZOTAROLIMUS ELUTING STENT; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DEVICES; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927693678     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000159     Document Type: Article

References (34)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
3. Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 2002;105:2986-2991.
4. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1264.
5. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.
6. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
9. Elezi S, Kastrati A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A. Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. Catheter Cardiovasc Interv 1999;48:151-156.
10. Kuntz RE, Safian RD, Carrozza JP, Fishman RF, Mansour M, Baim DS. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992;86:1827-1835.
11. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
12. Radke PW, Kaiser A, Frost C, Sigwart U. Outcome after treatment of coronary in-stent restenosis; results from a systematic review using metaanalysis techniques. Eur Heart J 2003;24:266-273.
13. Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, et al. RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004;43:943-949.
14. Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000;101:1895-1898.
15. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.
16. Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006;295:1264-1273.
17. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-2273.
18. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232.
19. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001;4:378-391.
20. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
21. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-1878.
22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
23. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-2180.
24. Lemos PA, van Mieghem CA, Arampatzis CA, Hoye A, Ong AT, McFadden E, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 2004;109:2500-2502.
25. Cosgrave J, Melzi G, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM, et al. Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006;47:2399-2404.
26. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, Airoldi F, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 2007;153:354-359.
27. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. Instent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-1907.
28. Kim YH, Lee BK, Park DW, Park KH, Choi BR, Lee CW, et al. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol 2006;98:1451-1454.
29. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Steinberg DH, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007;70:9-14.
30. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, et al. ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel-versus sirolimuseluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55:2710-2716.
31. Mishkel GJ, Moore AL, Markwell S, Shelton MC, Shelton ME. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007;49:181-184.
32. Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 2012;60:1733-1738.
33. Park DW, Hong MK, Mintz GS, Lee CW, Song JM, Han KH, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late 'catch-up' phenomenon from ASPECT Study. J Am Coll Cardiol 2006;48:2432-2439.
34. Kuriyama N, Kobayashi Y, Nakama T, Mine D, Nishihira K, Shimomura M, et al. Late restenosis following sirolimus-eluting stent implantation. JACC Cardiovasc Interv 2011;4:123-128.